Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone)

Alessandro Castriota-Scanderbeg, Michele Sacco

Research output: Contribution to journalArticlepeer-review

Abstract

A thalassaemic girl presented with agranulocytosis, arthritis of both ankles and clinical and laboratory features consistent with the diagnosis of systemic vasculitis, during oral iron chelator L1 (deferiprone) treatment. Changes in the humoral and cell-mediated immune function, including antinuclear antibodies (ANA), anti-DNA and extractable-nuclear antigens (ENA) antibodies positivity, increased immunoglobulin values, decreased T suppressor and the presence of circulating immune complexes, suggest a cause-and-effect relationship with the observed clinical manifestations. A careful monitoring of the immune function is recommended in patients who are receiving the oral iron chelator L1.

Original languageEnglish
Pages (from-to)254-255
Number of pages2
JournalBritish Journal of Haematology
Volume96
Issue number2
Publication statusPublished - 1997

Keywords

  • immune function
  • L1 (deferiprone)
  • thalassaemia major
  • vasculitis

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone)'. Together they form a unique fingerprint.

Cite this